Dilon buys Dune Medical's assets

Molecular breast imaging developer Dilon Diagnostics has acquired the assets of Dune Medical, including the company's MarginProbe device for identifying positive margins during breast conservation surgery.

Dilon said the acquisition will give the company the only device for identifying positive margins during breast conservation surgery that's approved by the U.S. Food and Drug Administration. MarginProbe uses radiofrequency (RF) technology to differentiate cancer from healthy tissue in real-time, reducing the need for reexcision.

Dilon believes that MarginProbe provides synergies with its own product line, such as its Navigator gamma-based probes.